HWK-206

2026年5月22日，杭州多禧生物科技有限公司（以下简称“多禧生物”）与Whitehawk Theraputics, Inc.（以下简称“Whitehawk”）共同宣布，双方近期正式达成了一项全新的战略协议。根据协议内容，Whitehawk将基于多禧生物极具竞争力的专利技术，开发最多5款创新抗体药物偶联物（ADC）。 在此次合作中，多禧生物将提供其专利毒素-连接子 CPT113 以及独家 CrossConju™ 定点搭桥工艺。作为协议的一部分，多禧生物有权在未来的产品许可协议中，获得可观的里程碑付款及产品销售提成。 此次协议的达成，是继2024年12月三方合作之后的又一次深度携手。此前，多禧生物已通过药明生物，将基于CPT113平台开发的三款ADC的全球权益授权给了Whitehawk（当时为Aadi Bioscience）。在那次合作中率先推进的三款ADC候选药物，目前已有2款进入临床阶段，第三款也即将迈入临床。 这一连串的合作成果，充分证明了Whitehawk对多禧生物核心技术平台的高度认可与信赖。多年来，多禧生物通过与国内外知名药企的深度技术合作，积累了极其宝贵的实战经验。其CrossConju™化学搭桥定点偶联技术和以CPT113为代表的Topo1抑制剂毒素-连接子技术，不仅已在多款合作和自研ADC产品中成功应用，更经受住了严苛的临床验证。 多禧生物的技术平台不仅服务于合作伙伴，更在国际顶尖学术舞台上大放异彩。在刚刚闭幕的AACR 2026年会上，多款备受瞩目的ADC产品均采用了多禧生物的技术：强生（JNJ-95437446）：发布的EGFR/cMET双抗ADC；Whitehawk Therapeutics：发布的HWK-007、HWK-016和HWK-206三个ADC产品。 在积极寻求对外技术合作、赋能全球创新药研发的同时，多禧生物也在马不停蹄地快速推进自有管线的临床开发。公司始终致力于解决未满足的临床需求，通过“自主研发+对外授权”的双轮驱动模式，共同为全球患者提供更多、更好的肿瘤治疗方案。 【关于杭州多禧生物科技有限公司】杭州多禧生物科技有限公司（多禧生物）于2012年底在杭州成立，公司目前拥有处于不同研发阶段的30多款ADC药物。经过10余年的研发沉淀，建立了具有自主知识产权的ADC药物技术平台，具备ADC药物从早期研发、工艺开发和商业化生产的全流程能力。公司在全球范围内拥有700余项专利申请，覆盖30多个国家和地区，其中35项专利申请已在美国获得授权。

Whitehawk Therapeutics (Nasdaq: WHWK) has entered an option agreement with China’s Hangzhou DAC Biotech to access the CPT113 linker-payload technology across up to five new ADC programs, including dual-payload variations. The Morristown, New Jersey-based Whitehawk, which relaunched from Aadi Bioscience in 2025 to focus on antibody-drug conjugates, will select targets and source antibodies independently while retaining global rights and full program control. Financial terms were not disclosed. CPT113 is a camptothecin-based topoisomerase I (Top1) inhibitor linker-payload developed by Hangzhou DAC. Top1 inhibitor payloads work by inducing DNA single-strand breaks in tumor cells, triggering apoptosis — the same mechanism used by DXd in trastuzumab deruxtecan (Enhertu) and SN-38 in sacituzumab govitecan (Trodelvy). Whitehawk describes CPT113 as a differentiated next-generation payload within this class, though the specific chemical distinctions from DXd and SN-38 are not fully disclosed in company materials. Whitehawk’s approach layers its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process on top of the CPT113 payload. CBCR is described by the company as a site-specific conjugation method that reduces the native interchain disulfide bonds of the antibody and re-bridges the resulting free cysteines using a carbon-based crosslinker, producing a more homogeneous ADC with a defined drug-to-antibody ratio (DAR). In nonclinical comparisons against Hangzhou DAC’s own CPT113-based ADC, DXC006, Whitehawk reported higher DAR and improved therapeutic index — though these data are preclinical and have not been validated in a controlled head-to-head clinical setting. Whitehawk’s existing three-asset pipeline — HWK-007, HWK-016, and HWK-206 — is separately in-licensed from WuXi Biologics (HKEX: 2269.HK) under an exclusive global development and commercialization agreement. The new Hangzhou DAC option expands the CPT113 access that already underpins those programs to cover up to five additional, internally developed candidates. The company anticipates submitting IND applications for multiple new programs within 12 to 24 months. Both of Whitehawk’s lead clinical programs are currently enrolling. HWK-007, a PTK7-directed ADC, received IND clearance in January 2026 and has completed the first dose cohort at 2 mg/kg in a Phase I trial evaluating patients with non-squamous EGFR wild-type NSCLC, platinum-resistant ovarian cancer, and endometrial cancer. HWK-016, a MUC16-directed ADC, entered Phase I first-in-human testing in March 2026 and is enrolling the first dose cohort at 2.5 mg/kg in ovarian and endometrial cancers (NCT07470853). Initial data from both programs are expected in the first half of 2027. An IND for HWK-206 is anticipated mid-year 2026. Whitehawk cited two external programs using CPT113 as validation for the payload’s clinical credentials. Hangzhou DAC’s DXC006, a CD56-directed ADC, is in a Phase I dose-escalation and expansion study in China (NCT06224855) in SCLC, NSCLC, and neuroendocrine neoplasms, with data accepted for oral presentation at ASCO 2026. Johnson & Johnson (NYSE: JNJ) separately disclosed JNJ-95437446, an amivantamab-based EGFR/MET ADC using CPT113, at AACR 2026, supported by preclinical data from an ongoing Phase I trial (NCT07107230). The option structure — covering up to five programs with global rights retained by Whitehawk and no disclosed economics — is consistent with multi-target payload licensing arrangements that have become common in the ADC space, where linker-payload providers grant access to platform technology on a per-program basis rather than through single-asset deals. In January 2026, Lonza’s Synaffix unit signed a multi-target license agreement with Sidewinder Therapeutics to advance next-generation bispecific ADCs using Synaffix’s clinically validated ADC platform — a structurally comparable arrangement in which the technology provider licenses access across multiple programs while the drug developer controls target selection and development. The timing of the Hangzhou DAC agreement coincides with rising pharma interest in the CPT113 payload specifically. J\&J’s use of CPT113 in an amivantamab-based ADC is a notable signal, given that amivantamab is an approved bispecific targeting EGFR and MET. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.